Literature DB >> 27065711

Preoperative Preparation and Patient Selection for Cytoreductive Surgery and HIPEC.

Rangole Ashvin1, Jain Nikhilesh2.   

Abstract

Peritoneal dissemination is a significant variable affecting long term survival of abdominal cancer patients. A generally accepted clinical point of view is that peritoneal dissemination is tantamount to distant organ metastases. This implies it to be a terminal condition. Current practice dictates that if peritoneal dissemination is observed intraoperatively, the curative therapeutic options are deferred and comprehensive systemic chemotherapy remains the only option with a dismal prognosis. The past few years have generated lot of interest in management of peritoneal carcinomatosis. Prof Paul Sugarbaker has researched, validated and fine-tuned the concept of cytoreductive surgery with peritonectomy procedure (Sugarbaker technique) and perioperative chemotherapy as HIPEC & EPIC. Recognition of a HIPEC centre is based on an infrastructure equipped with basic knowledge of the tumor biology, oncosurgical techniques, technical knowhow for HIPEC administration, intensive care unit etc. There are some aspects which need to be accorded special consideration. Comprehensive therapy of Cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is initiated with exploration and cytoreductive surgery and includes visceral resections and peritonectomy procedure when achieved optimally results in complete, visible resection of all cancer within the abdomen and pelvis. Subsequent to CRS, HIPEC forms an integral part of the surgical procedure. This approach involves conceptual changes in both the route and timing of chemotherapy administration. Patient selection is of utmost importance. The greatest impediment to lasting benefits from intraperitoneal chemotherapy remains an improper patient selection. Currently, there are four important clinical assessments of peritoneal metastasis that need to be used to select patients ie; histopathological type of tumour, radiological distribution of disease, peritoneal cancer index and completeness of cytoreduction. Patients undergoing HIPEC surgery face the usual physiological insults of a major surgery in addition to the thermal stress secondary to intraperitoneal administration of heated chemotherapy agent. A team approach of everyone involved in care of these patients is known to improve patient outcomes. It has also been observed that with the necessary preoperative & perioperative steps, the morbidity and mortality for this treatment can be brought down as comparable to any other major abdominal surgeries.

Entities:  

Keywords:  Cytoreductive surgery & HIPEC; Patient selection; Peritoneal carcinomatosis; Preoperative management

Year:  2016        PMID: 27065711      PMCID: PMC4818610          DOI: 10.1007/s13193-016-0514-4

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  19 in total

Review 1.  Anesthetic management in patients undergoing hyperthermic chemotherapy.

Authors:  Christoph Raspe; Pomipilu Piso; Christoph Wiesenack; Michael Bucher
Journal:  Curr Opin Anaesthesiol       Date:  2012-06       Impact factor: 2.706

2.  ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery.

Authors:  Lee A Fleisher; Joshua A Beckman; Kenneth A Brown; Hugh Calkins; Elliott Chaikof; Kirsten E Fleischmann; William K Freeman; James B Froehlich; Edward K Kasper; Judy R Kersten; Barbara Riegel; John F Robb; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; Christopher E Buller; Mark A Creager; Steven M Ettinger; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  Circulation       Date:  2007-09-27       Impact factor: 29.690

Review 3.  Anesthesia considerations during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Kenneth P Rothfield; Kathy Crowley
Journal:  Surg Oncol Clin N Am       Date:  2012-08-26       Impact factor: 3.495

4.  Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment.

Authors:  B Berthet; T A Sugarbaker; D Chang; P H Sugarbaker
Journal:  Eur J Cancer       Date:  1999-03       Impact factor: 9.162

5.  Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.

Authors:  Pascal Owusu-Agyemang; Radha Arunkumar; Holly Green; Darline Hurst; Kathryn Landoski; Andrea Hayes-Jordan
Journal:  Ann Surg Oncol       Date:  2012-03-27       Impact factor: 5.344

6.  Peritoneal Surface Oncology: A progress report.

Authors:  Santiago González-Moreno
Journal:  Eur J Surg Oncol       Date:  2006-04-05       Impact factor: 4.424

7.  Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis.

Authors:  Ju-Li Koh; Tristan D Yan; Derek Glenn; David L Morris
Journal:  Ann Surg Oncol       Date:  2008-12-03       Impact factor: 5.344

8.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

Authors:  O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

9.  Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features.

Authors:  A G Portilla; P H Sugarbaker; D Chang
Journal:  World J Surg       Date:  1999-01       Impact factor: 3.352

10.  Learning curve of combined modality treatment in peritoneal surface disease.

Authors:  R M Smeenk; V J Verwaal; F A N Zoetmulder
Journal:  Br J Surg       Date:  2007-11       Impact factor: 6.939

View more
  2 in total

1.  Physical, psychological and nutritional outcomes in a cohort of Irish patients with metastatic peritoneal malignancy scheduled for cytoreductive surgery (CRS) and heated intrapertioneal chemotherapy (HIPEC): An exploratory pilot study.

Authors:  Lisa Loughney; Noel McCaffrey; Claire M Timon; Joshua Grundy; Andrew McCarren; Ronan Cahill; Niall Moyna; Jurgen Mulsow
Journal:  PLoS One       Date:  2020-12-09       Impact factor: 3.240

Review 2.  Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis.

Authors:  Maciej Nowacki; Margarita Peterson; Tomasz Kloskowski; Eleanor McCabe; Delia Cortes Guiral; Karol Polom; Katarzyna Pietkun; Barbara Zegarska; Marta Pokrywczynska; Tomasz Drewa; Franco Roviello; Edward A Medina; Samy L Habib; Wojciech Zegarski
Journal:  Oncotarget       Date:  2017-08-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.